

**Supporting Information for
Targeting STING oligomerization with small-molecule inhibitors**

Fiachra Humphries^{1,6*}, Liraz Shmuel-Galia^{1,6}, Zhaozhao Jiang¹, Jeffrey Y. Zhou¹, Leonard Barasa², Santanu Mondal^{2,3}, Ruth Wilson¹, Nadia Sultana^{2,4}, Scott A Shaffer^{2,4}, Sze-Ling Ng⁵, G. Scott Pesiridis⁵, Paul R. Thompson^{2,*} and Katherine A. Fitzgerald^{1,*}

*Correspondence to: Fiachra.Humphries@umassmed.edu
Paul.Thompson@umassmed.edu
Kate.Fitzgerald@umassmed.edu

This PDF file includes:

Figures S1 to S4

A**BB-Cl-Yne**

sp|Q3TB3|STING_MOUSE (100%), 42,831.5 Da
 sp|Q3TB3|STING_MOUSE Stimulator of interferon genes protein OS=Mus musculus OX=10090 GN=Tmem173
 6 exclusive unique peptides, 7 exclusive unique spectra, 7 total spectra, 89/378 amino acids (24% coverage)

```

MPYSNLHPAI PRRGRHRSKY VALIFLVASL MILWVAKDPP NHTLKYLALH
LASHELGLLL KNLCCLAEEL CHVOSRYQGS YWKAVRACLG CPIHCMAMIL
LSSYFYFLON TADIYLSWMF GLLVLYKSLSL MLLGLOS LTP AEVSADVCEEK
KLNVVAHGLAW SYYIGYLRLLI LPGLOARIRM FNOLHNNMLS GAGSRRYLIL
FPLDCGVPDN LSVVDPNIRF RDMLPQONID RAGIKNRVYS NSVYEEILENG
OPAGVCILEY ATPQOTLFAM SODAKAGFSR EDRLEOAQLF CRTLEEILED
VPESRNNCRL IVYOEPDTGN SFSLSOEVLR HIRQEEKEEV TMNAPMTSVA
PPPSVLSQEP RLLISGMQDP LPLRTDLI
  
```


B**BB-Cl-Yne + BB-Cl**

sp|Q3TB3|STING_MOUSE (100%), 42,831.5 Da
 sp|Q3TB3|STING_MOUSE Stimulator of interferon genes protein OS=Mus musculus OX=10090 GN=Tmem173
 1 exclusive unique peptides, 1 exclusive unique spectra, 1 total spectra, 10/378 amino acids (3% coverage)


```

MPYSNLHPAI PRRGRHRSKY VALIFLVASL MILWVAKDPP NHTLKYLALH
LASHELGLLL KNLCCLAEEL CHVOSRYQGS YWKAVRACLG CPIHCMAMIL
LSSYFYFLON TADIYLSWMF GLLVLYKSLSL MLLGLOS LTP AEVSADVCEEK
KLNVVAHGLAW SYYIGYLRLLI LPGLOARIRM FNOLHNNMLS GAGSRRYLIL
FPLDCGVPDN LSVVDPNIRF RDMLPQONID RAGIKNRVYS NSVYEEILENG
OPAGVCILEY ATPQOTLFAM SODAKAGFSR EDRLEOAQLF CRTLEEILED
VPESRNNCRL IVYOEPDTGN SFSLSOEVLR HIRQEEKEEV TMNAPMTSVA
PPPSVLSQEP RLLISGMQDP LPLRTDLI
  
```


Supplementary Figure 1. BB-Cl-amidine binds to STING. (A–B) Sequence coverage of STING from analysis of peptides identified in streptavidin bead pull-downs from clicked lysates of BMDMs treated with BB-Cl-Yne (A) or BMDMs co-treated with BB-Cl-amidine and BB-Cl-Yne (B) (related to Figure 4). Representative of 3 independent replicates.



Supplementary Figure 2. IRF3 deficiency protects against experimental AGS in Trex1D18N/D18N mice. (A) Survival analysis of WT (n=20), Trex1^{D18N/D18N} (n=20), Trex1^{D18N/D18N}/Irf3^{-/-} mice (n=20). (B) Spleen weights of WT (n=5), Trex1^{D18N/D18N} (n=6), Trex1^{D18N/D18N}/Irf3^{-/-} mice (n=17). (C) ELISA analysis of serum Cxcl10 in WT (n=10), Trex1^{D18N/D18N} (n=9), Trex1^{D18N/D18N}/Irf3^{-/-} mice (n=9). (D-E) Representative H&E staining of tissue sections from hearts (D) and pathology evaluation of heart sections (E) from WT (n=5) and Trex1^{D18N/D18N} (n=9) and Trex1^{D18N/D18N}/Irf3^{-/-} mice (n=9). *, P<0.05, **, P<0.01 by two-way ANOVA. Error bars show means ± SEM.



Supplementary Figure 3. STING deficiency and cGAMP binding blockade protect against experimental AGS in Trex1^{D18N/D18N} mice. (A) Survival analysis of WT (n=10), Trex^{D18N/D18N} (n=20) and Trex1^{D18N/D18N}/STING^{-/-} (n=10) and Trex1^{D18N/D18N}/STING^{R237A/R237A} (n=10) mice. (B) Spleen weights of WT (n=10), Trex1^{D18N/D18N} (n=8), Trex1^{D18N/D18N}/STING^{-/-} (n=10) and Trex1^{D18N/D18N}/STING^{R237A/R237A} (n=10) mice. (C-D) Representative H&E staining (C) and pathology scoring of tissue sections from hearts (D) of WT (n=3), Trex1^{D18N/D18N} (n=4) and Trex1^{D18N/D18N}/STING^{-/-} (n=4) and Trex1^{D18N/D18N}/STING^{R237A/R237A} (n=4) mice., ***, P<0.001. two-way ANOVA. Error bars show means ± SEM.



Supplementary Figure 4. BB-Cl-amidine modifies Cys²⁰⁶, Cys²⁵⁷ and Cys³⁰⁹ in STING. (A-C)
Representative mass spectrometry spectra of STING modified by BB-Cl-amidine AT Cys²⁰⁶ (A), Cys²⁵⁷ (B) and Cys³⁰⁹ (C) identified in tryptic digests from recombinant STING (10 µg) incubated with BB-Cl-amidine (10 µM) for 1 h at 37 °C.